Market News

Curis, Inc. (CRIS) Reaches $0.80 52 Week Low; Belden (BDC)’s Sentiment Is 1

The stock of Curis, Inc. (NASDAQ:CRIS) hit a new 52-week low and has $0.73 target or 9.00% below today’s $0.80 share price. The 7 months bearish chart indicates high risk for the $130.86M company. The 1-year low was reported on Dec, 7 by Barchart.com. If the $0.73 price target is reached, the company will be worth $11.78 million less. The stock decreased 2.45% or $0.02 during the last trading session, reaching $0.798. About 631,039 shares traded. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since December 7, 2016 and is uptrending. It has underperformed by 14.23% the S&P500.

Belden Inc. designs, manufactures, and markets signal transmission solutions worldwide. The company has market cap of $3.46 billion. The Company’s Broadcast Solutions segment offers camera solutions, production switchers, server and storage systems for instant replay applications, interfaces and routers, monitoring systems, network and playout systems, plant connectivity products, and cable and connectivity products for television broadcast, cable, satellite, and IPTV industries. It has a 57.01 P/E ratio. The companyÂ’s Enterprise Connectivity Solutions segment provides copper cable and connectivity solutions, fiber cable and connectivity solutions, and racks and enclosures; and power, cooling, and airflow management products for mission-critical data center operations.

Analysts await Curis, Inc. (NASDAQ:CRIS) to report earnings on March, 8. They expect $-0.09 earnings per share, down 12.50% or $0.01 from last year’s $-0.08 per share. After $-0.11 actual earnings per share reported by Curis, Inc. for the previous quarter, Wall Street now forecasts -18.18% EPS growth.

Among 6 analysts covering Curis (NASDAQ:CRIS), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Curis had 8 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Sell” rating by Zacks given on Monday, September 21. The company was initiated on Monday, October 23 by Guggenheim. Zacks downgraded the stock to “Hold” rating in Tuesday, September 1 report. The stock of Curis, Inc. (NASDAQ:CRIS) earned “Buy” rating by TH Capital on Monday, November 9. The firm earned “Outperform” rating on Tuesday, August 11 by FBR Capital. The stock of Curis, Inc. (NASDAQ:CRIS) earned “Buy” rating by Roth Capital on Monday, November 9.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $130.86 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.15, from 1.37 in 2017Q1. It improved, as 9 investors sold Curis, Inc. shares while 20 reduced holdings. 14 funds opened positions while 30 raised stakes. 72.75 million shares or 0.77% less from 73.32 million shares in 2017Q1 were reported. Nationwide Fund Advsrs stated it has 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Bridgeway Cap Mgmt holds 0% in Curis, Inc. (NASDAQ:CRIS) or 84,160 shares. 100,023 are held by Manufacturers Life Insurance The. Legal And General Group Inc Public Limited Co holds 0% in Curis, Inc. (NASDAQ:CRIS) or 29,560 shares. Wells Fargo And Mn invested 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Amer Int stated it has 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Weiss Multi reported 125,000 shares. Meridian Inv Counsel invested 0.01% in Curis, Inc. (NASDAQ:CRIS). Vident Inv Advisory Ltd Llc stated it has 636,635 shares or 0.1% of all its holdings. 155,470 were reported by Jacobs Levy Equity Mngmt. Rhumbline Advisers has invested 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Gp One Trading L P owns 9,427 shares. Blackrock holds 0% or 9.36 million shares. 12,243 were accumulated by Bnp Paribas Arbitrage. Moreover, Renaissance Techs Limited Liability Corporation has 0% invested in Curis, Inc. (NASDAQ:CRIS).

The stock decreased 0.24% or $0.2 during the last trading session, reaching $82.09. About 50,828 shares traded. Belden Inc. (BDC) has risen 12.57% since December 7, 2016 and is uptrending. It has underperformed by 4.13% the S&P500.

Stanley Capital Management Llc holds 3.34% of its portfolio in Belden Inc. for 70,000 shares. Lapides Asset Management Llc owns 221,400 shares or 3.23% of their US portfolio. Moreover, Channing Capital Management Llc has 2.91% invested in the company for 986,271 shares. The New York-based Basswood Capital Management L.L.C. has invested 2.71% in the stock. Skyline Asset Management Lp, a Illinois-based fund reported 304,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *